Hospital Mãe de Deus - Centro Integrado de Oncologia

Porto Alegre, Rio Grande do Sul 91210-250

0 studies enrolling now · 3 studies all time

What they study most

Adjuvant, Advanced or Metastatic NSCLS With Exon 20 Insertion Mutation, EGFR, Early Stage Lung Cancer, Exon 20, Lung Cancer, NSCLC, Stage IB-IIIA, Post-surgical, Refractory Diffuse Large B-Cell Lymphoma, Relapsed Diffuse Large B-Cell Lymphoma, Uncommon EGFR Mutations

Studies at this site

• REZILIENT3 (REsearching ZIpaLertinib In Egfr Non-small Cell Lung Cancer Tumors) — Running, not enrolling
• A Study to Assess the Efficacy and Safety of Zipalertinib Versus Placebo for Adjuvant Treatment in Participants With Stage IB-IIIA NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection — Running, not enrolling
• Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma — Running, not enrolling